Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Waldenström's macroglobulinemia.

K R Desikan1, M V Dhodapkar, B Barlogie

  • 1Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, 4301 W. Markham Slot-776, Little Rock, AR, 72205, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Leukemia·2018
Same author

Drug response prediction in high-risk multiple myeloma.

Gene·2017
Same author

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Nature communications·2017
Same author

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.

Leukemia·2017
Same author

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

Leukemia·2017
Same author

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Blood cancer journal·2017
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Waldenström's macroglobulinemia (WM) management varies by prognosis. Patients with low beta2 microglobulin and normal hemoglobin may be monitored. Achieving complete remission requires a comprehensive strategy, potentially including Rituxan and stem cell transplantation.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Waldenström's macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with variable clinical behavior.
  • Prognosis in WM is heterogeneous, with some patients requiring immediate treatment while others can be observed.
  • Serum beta2 microglobulin and hemoglobin levels are key indicators for treatment decisions in WM.

Purpose of the Study:

  • To review the prognostic factors and therapeutic strategies for Waldenström's macroglobulinemia.
  • To emphasize the importance of achieving and sustaining complete remissions for improved patient outcomes.
  • To outline a comprehensive approach for managing WM, particularly in relapsed or refractory cases.

Main Methods:

  • Review of existing literature on Waldenström's macroglobulinemia diagnosis, prognosis, and treatment.

Related Experiment Videos

  • Analysis of prognostic markers such as serum beta2 microglobulin and hemoglobin.
  • Discussion of therapeutic options including observation, chemotherapy, and novel agents.

    • Main Results:

    • Asymptomatic WM patients with low beta2 microglobulin and preserved hemoglobin can be safely observed.
    • Conventional therapies like alkylating agents and purine analogs often achieve partial, not complete, remissions.
    • Salvage therapy with purine analogs can be effective in patients refractory to initial treatments.

    Conclusions:

    • A comprehensive treatment strategy is essential for improving outcomes in Waldenström's macroglobulinemia.
    • Incorporating Rituxan, stem cell procurement, high-dose therapy, and interferon maintenance may enhance complete remission rates.
    • Personalized management based on prognostic factors is crucial for effective WM care.